Catalyst Oncology is a specialty oncology contract research organization (CRO) devoting time, energy, and capital to supporting biotechs in bringing next-generation antibody drug conjugates (ADC) therapies to cancer patients.
Oncology clinical research is complex, demanding, and continually evolving. Bringing effective ADC therapies to proof-of-concept and then to market as fast as possible are our focus because every second counts for patients with cancer and their families.
Robust pipeline of ADC trials
We understand the nuances of ADC trials
Exclusively biotech-focused
Built to work exclusively with biotechs, our flexible processes and approach allow us to listen first, align goals, and execute with an eye toward rapid shifts when protocols amend, or Breakthrough designations move a product straight from Phase I to registration.
Seasoned oncology experts
With an average of 9+ years of oncology experience for key roles (PM, CTL, DM, Clinical Science), our oncology specialty guarantees you a seasoned team across all functions.
Additional differentiators
Active next-gen oncology experience
Working both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies.
